BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2020 7:36:12 AM | Browse: 335 | Download: 685
Publication Name World Journal of Gastroenterology
Manuscript ID 58599
Country/Territory United States
2020-08-03 22:25
Peer-Review Started
2020-08-03 22:25
To Make the First Decision
Return for Revision
2020-09-12 06:22
2020-09-30 13:56
Second Decision
2020-10-19 08:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-10-20 04:17
Articles in Press
2020-10-20 04:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-11-02 03:18
Publish the Manuscript Online
2020-11-06 07:36
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Efficacy and safety of anti-hepatic fibrosis drugs
Manuscript Source Invited Manuscript
All Author List Konstantinos Damiris, Zaid H Tafesh and Nikolaos Pyrsopoulos
Author(s) ORCID Number
Konstantinos Damiris http://orcid.org/0000-0001-9972-740X
Zaid H Tafesh http://orcid.org/0000-0002-3927-9569
Nikolaos Pyrsopoulos http://orcid.org/0000-0002-6950-8174
Funding Agency and Grant Number
Corresponding Author Nikolaos Pyrsopoulos, FACP, MD, PhD, Director, Doctor, Professor, Medicine-Gastroenterology and Hepatology, Rutgers-New Jersey Medical School, 185 S. Orange Avenue, MSB H-535, Newark, NJ 07103, United States. pyrsopni@njms.rutgers.edu
Key Words Liver; Fibrosis; Cirrhosis; Antifibrotic; Pharmacotherapy; Clinical trial
Core Tip A number of clinical trials have targeted various etiologies of liver fibrosis and cirrhosis. Some have been promising, particularly in metabolic associated fatty liver disease and viral hepatitis. Results from these studies have shown that there are safe treatments available, forming currently practiced therapeutic guidelines, and shining light on the potential reversibility of liver fibrosis and cirrhosis caused by a variety of etiologies.
Publish Date 2020-11-06 07:36
Citation Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321
URL https://www.wjgnet.com/1007-9327/full/v26/i41/6304.htm
DOI https://dx.doi.org/10.3748/wjg.v26.i41.6304
Full Article (PDF) WJG-26-6304.pdf
Full Article (Word) WJG-26-6304.docx
Manuscript File 58599_Auto_Edited.docx
Answering Reviewers 58599-Answering reviewers.pdf
Audio Core Tip 58599-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 58599-Conflict-of-interest statement.pdf
Copyright License Agreement 58599-Copyright license agreement.pdf
Peer-review Report 58599-Peer-review(s).pdf
Scientific Misconduct Check 58599-Scientific misconduct check.pdf
Scientific Editor Work List 58599-Scientific editor work list.pdf